stocksONESOURCE
ONESOURCE

Onesource Specialty Pharma Ltd.

1,638.80+26.8 (+1.66%)
9 Jul, 2:29 PM

Income Statement

Abridged
Understanding Income Statement
Onesource Specialty Pharma Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.
2023
Mar 31
2024
Mar 31
2025
Mar 31
2026
Mar 31
Period length:
Source:
12M
AR
12M
AR
12M
AR
12M
PRESS
Total Revenue
391721,4451,422
Cost of Operating Revenue
106167745724
Gross Profit
-675700698
Gross Margin
-174.32.948.449.1
Total Operating Expenses
2553301,2501,396
Operating Profit
-216-15819425
Operating Margin
-559.2-92.013.51.8
Financing Income/(Expense) - Net
-55-88-152-122
Profit before Taxes
-416-366-67-92
Income Taxes
---50-18
Profit after Tax
-800-391-18-74
PAT Margin
-2,066.0-227.5-1.2-5.2
EPS - Basic - ex Extraordinary Items
-36.32-31.96-1.57-6.44
EPS - Diluted - ex Extraordinary Items
-36.32-31.96-1.57-6.44
EBIT
-216-15819425
EBITDA
-102-63468304
EBITDA Margin
-264.5-36.532.421.4

Balance Sheet

Abridged
Understanding Balance Sheet
Onesource Specialty Pharma Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.
2023
Mar 31
2024
Mar 31
2025
Mar 31
2026
Mar 31
Source:
AR
AR
AR
PRESS
Total Current Assets
2281761,0861,426
Long-Term Investments
--710
Property Plant & Equipment - Net
1,3587259581,240
Total Non-Current Assets
1,7801,1326,4646,784
Total Assets
2,0091,3097,5508,210
Total Current Liabilities
8656311,1141,442
Long Term Debt
356280383782
Total Non-Current Liabilities
358282556937
Total Liabilities
1,2239131,6702,379
Total Shareholders' Equity
7853965,8815,831
Total Equity
7853965,8815,831
Total Liabilities & Equity
2,0091,3097,5508,210

Cash Flow

Abridged
Understanding Cash Flow Statement
Onesource Specialty Pharma Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.
2023
Mar 31
2024
Mar 31
2025
Mar 31
2026
Mar 31
Period length:
Source:
12M
AR
12M
AR
12M
AR
12M
PRESS
Operating CF bef Changes in Working Cap
97.46-177.95209.41166.00
Working Capital - Increase/(Decrease)
21.70-4.13-419.89-276.57
Net CF from Operating Activities
119.16-182.08-210.48-110.58
Capital Expenditures - Net
43.99102.79128.06569.06
Net CF from Investing Activities
-70.87507.60-214.31-494.98
Stock - Issuance/(Retirement) - Net
564.76-875.525.75
Debt - LT & ST - Issuance/(Retirement) - Total
-332.64-280.70-285.99472.79
Net Cash Flow from Financing Activities
232.12-280.70589.54478.54
Free Cash Flow to Equity
-257.47-565.58-624.52-206.84
Free Operating CF net dividend
75.17-285.27-338.63-679.65
Free Operating CF
75.17-285.27-338.63-679.65

Business Segment Analysis

FY End:
Mar 25

Onesource Specialty Pharma Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales
Total₹ 1,445Cr
CDMO (100.0%)₹ 1,444.85 Cr

Regional Segment Analysis

FY End:
Mar 25

Onesource Specialty Pharma Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales
Total₹ 1,445Cr
Rest of the world (39.4%)₹ 569.44 CrUnited States of America (USA) (35.0%)₹ 506.25 CrIndia (13.4%)₹ 194.15 CrIreland (12.1%)₹ 175.02 Cr

Historical Segment Analysis

Track how Onesource Specialty Pharma Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Business
We don't have enough data to show the Capex for Onesource Specialty Pharma Ltd..

Frequently Asked Questions

What is the revenue of Onesource Specialty Pharma Ltd.?
The latest trailing twelve month revenue of Onesource Specialty Pharma Ltd. is ₹ 1,421.59 Cr, reflecting a 1-year growth of -1.61% and a 3-year CAGR of 232.38%. Annual and quarterly revenue trends are available in the Income Statement section.
What is the net profit of Onesource Specialty Pharma Ltd.?
The latest trailing twelve month net profit (PAT) of Onesource Specialty Pharma Ltd. is ₹ -73.80 Cr, with a 3-year earnings CAGR of 43.82%. Detailed profit history across annual and quarterly periods is in the Income Statement section.
What is the EBITDA of Onesource Specialty Pharma Ltd.?
The trailing twelve month EBITDA of Onesource Specialty Pharma Ltd. is approximately ₹ 25.13 Cr (based on an operating margin of 1.77%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.
What is the EPS of Onesource Specialty Pharma Ltd.?
The trailing twelve month Earnings Per Share (EPS) of Onesource Specialty Pharma Ltd. is -6.44. EPS trends across annual and quarterly periods are visible in the Income Statement section.
What is the debt level of Onesource Specialty Pharma Ltd.?
The debt-to-equity ratio of Onesource Specialty Pharma Ltd. stands at 0.26. The interest coverage ratio is 0.21x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.
What is the book value per share of Onesource Specialty Pharma Ltd.?
The estimated book value per share of Onesource Specialty Pharma Ltd. is 517.09 (derived from a P/B ratio of 3.17 and market price of ₹ 1,638.80), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.
What is the cash flow from operations of Onesource Specialty Pharma Ltd.?
The trailing twelve month operating cash flow of Onesource Specialty Pharma Ltd. is ₹ -110.58 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.
Does Onesource Specialty Pharma Ltd. report consolidated or standalone financials?
Onesource Specialty Pharma Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.